丽珠医药(01513.HK)：莱康奇塔单抗注射液上市许可申请获国家药品监督管理局受理

Core Viewpoint - Lijun Pharmaceutical (01513.HK) announced that its subsidiary, Zhuhai Lijun Monoclonal Antibody Biotechnology Co., Ltd., received the acceptance notice from the National Medical Products Administration for the registration application of the monoclonal antibody injection, Laikangqita, developed in collaboration with Beijing Xinkanghe Biological Pharmaceutical Technology Co., Ltd. [1] Group 1 - The acceptance notice is identified by the acceptance number CXSS2500144 [1] - The drug registration application is for domestic production [1] - The collaboration involves Lijun Monoclonal Antibody and Beijing Xinkanghe [1]